esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
Published 4 years ago • 2.1K plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
2:21
lba41 - leap-005: phase ii study of lenvatinib plus pembrolizumab
-
1:16
dr. lwin on the results of the leap-005 trial in advanced solid tumors
-
6:38
lenvatinib plus pembrolizumab for advanced melanoma that progressed on a pd-1 or pd-l1 inhibitor...
-
2:26
esmo 2020 highlights on alpelisib plus fulvestrant for hr /her2– abc: the solar-1 study
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
3:04
esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
2:35
esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
2:44
leap-015: lenvatinib pembrolizumab mfolfox6 in advanced/met gastroesophageal adenocarcinoma
-
4:02
#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
0:56
treating patients with melanoma who progressed on anti-pd-l1 with lenvatinib and pembrolizumab
-
1:00
esmo 2022 highlights
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma